OC9 Stock Overview
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Omnicell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.20 |
| 52 Week High | US$71.00 |
| 52 Week Low | US$24.00 |
| Beta | 0.76 |
| 1 Month Change | 0.77% |
| 3 Month Change | -17.61% |
| 1 Year Change | -51.03% |
| 3 Year Change | -77.41% |
| 5 Year Change | -63.45% |
| Change since IPO | 198.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| OC9 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 7.4% | -0.6% | 1.8% |
| 1Y | -51.0% | -9.5% | 2.2% |
Return vs Industry: OC9 underperformed the German Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: OC9 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| OC9 volatility | |
|---|---|
| OC9 Average Weekly Movement | 7.3% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OC9 has not had significant price volatility in the past 3 months.
Volatility Over Time: OC9's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,650 | Randy Lipps | www.omnicell.com |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software.
Omnicell, Inc. Fundamentals Summary
| OC9 fundamental statistics | |
|---|---|
| Market cap | €1.22b |
| Earnings (TTM) | -€19.06m |
| Revenue (TTM) | €1.07b |
1.1x
P/S Ratio-64.1x
P/E RatioIs OC9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OC9 income statement (TTM) | |
|---|---|
| Revenue | US$1.15b |
| Cost of Revenue | US$647.18m |
| Gross Profit | US$499.93m |
| Other Expenses | US$520.30m |
| Earnings | -US$20.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 43.58% |
| Net Profit Margin | -1.78% |
| Debt/Equity Ratio | 47.9% |
How did OC9 perform over the long term?
See historical performance and comparison